Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis

Molecular Cancer Therapeutics

Volumn 7, Issue 7, 2008, Pages 1940-1948

  Kraus, Marianne ^a   Malenke, Elke ^a   Gogel, Jeannette ^a   Müller, Holger ^a   Rückrich, Thomas ^a   Overkleeft, Herman ^b   Ovaa, Huib ^c   Koscielniak, Ewa ^d   Hartmann, Jörg Thomas ^a   Driessen, Christoph ^a,e  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b LEIDEN UNIVERSITY   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d OLGAHOSPITAL   (Germany)

^e CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 6; BORTEZOMIB; CASPASE 4; CASPASE 9; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; PROTEIN IRE1; RITONAVIR; STRESS ACTIVATED PROTEIN KINASE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PROTEASOME; PROTEIN SUBUNIT; PYRAZINE DERIVATIVE; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; ENZYME ACTIVE SITE; HUMAN; HUMAN CELL; HYPOTHESIS; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN SYNTHESIS; SARCOMA CELL; UNFOLDED PROTEIN RESPONSE; BINDING SITE; BIOSYNTHESIS; CELL CYCLE G2 PHASE; CELL DEATH; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENDOPLASMIC RETICULUM; METABOLISM; PATHOLOGY; SARCOMA; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING SITES; BORONIC ACIDS; CELL DEATH; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOPLASMIC RETICULUM; G2 PHASE; HUMANS; NEOPLASM PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BIOSYNTHESIS; PROTEIN FOLDING; PROTEIN SUBUNITS; PYRAZINES; RITONAVIR; SARCOMA;

EID: 51049124323     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-2375     Document Type: Article

References (36)

1. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005;23:630-9.
2. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002;82:373-428.
3. Altun M, Galardy PJ, Shringarpure R, et al. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. Cancer Res 2005;65:7896-901.
4. Lightcap ES, McCormack TA, Pien CS, et al. Proteasome inhibition measurements: clinical application. Clin Chem 2000;46:673-83.
5. Ovaa H, van Swieten PF, Kessler BM, et al. Chemistry in living cells: detection of active proteasomes by a two-step labeling strategy. Angew Chem Int Ed Engl 2003;42:3626-9.
6. Gass JN, Gunn KE, Sriburi R, Brewer JW. Stressed-out B cells? Plasma-cell differentiation and the unfolded protein response. Trends Immunol 2004;25:17-24.
7. Zhang K, Kaufman RJ. The unfolded protein response: a stress signaling pathway critical for health and disease. Neurology 2006;66:S102-9.
8. Davenport EL, Moore HE, Dunlop AS, et al. Heat shock protein inhibition is associated with activation of the unfolded protein response (UPR) pathway in myeloma plasma cells. Blood 2007;110:2641-9.
9. Catley L, Weisberg E, Kiziltepe T, et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006;108:3441-9.
10. Nawrocki ST, Carew JS, Dunner K Jr, et al. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res 2005;65:11510-9.
11. Zhou H, Pandak WM Jr, Lyall V, Natarajan R, Hylemon PB. HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease. Mol Pharmacol 2005;68:690-700.
12. Sgadari C, Monini P, Barillari G, Ensoli B. Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. Lancet Oncol 2003;4:537-47.
13. Gaedicke S, Firat-Geier E, Constantiniu O, et al. Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. Cancer Res 2002;62:6901-8.
14. Dewan MZ, Uchihara JN, Terashima K, et al. Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir. Blood 2006;107:716-24.
15. Pati S, Pelser CB, Dufraine J, et al. Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood 2002;99:3771-9.
16. Glas R, Bogyo M, McMaster JS, Gaczynska M Ploegh HL. A proteolytic system that compensates for loss of proteasome function. Nature 1998;392:618-22.
17. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-9.
18. Berkers CR, Verdoes M, Lichtman E, et al. Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods 2005;2:357-62.
19. Greiner A, Lautwein A, Overkleeft HS, Weber E, Driessen C. Activity and subcellular distribution of cathepsins in primary human monocytes. J Leukoc Biol 2003;73:235-42.
20. Driessen C, Bryant RA, Lennon-Dumenil AM, et al. Cathepsin S controls the trafficking and maturation of MHC class II molecules in dendritic cells. J Cell Biol 1999;147:775-90.
21. Kraus M, Ruckrich T, Reich M, et al. Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells. Leukemia 2007;21:84-92.
22. Andre P, Groettrup M, Klenerman P, et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci U S A 1998;95:13120-4.
23. Pajonk F, Himmelsbach J, Riess K, Sommer A, McBride WH. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res 2002;62:5230-5.
24. Schmidtke G, Holzhutter HG, Bogyo M, et al. How an inhibitor of the HIV-I protease modulates proteasome activity. J Biol Chem 1999;274:35734-40.
25. Scriven P, Brown NJ, Pockley AG, Wyld L. The unfolded protein response and cancer: a brighter future unfolding? J Mol Med 2007;85:331-41.
26. Obeng EA, Carlson LM, Gutman DM, et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006;107:4907-16.
27. Feldman DE, Chauhan V, Koong AC. The unfolded protein response: a novel component of the hypoxic stress response in tumors. Mol Cancer Res 2005;3:597-605.
28. Koumenis C, Wouters BG. "Translating" tumor hypoxia: unfolded protein response (UPR)-dependent and UPR-independent pathways. Mol Cancer Res 2006;4:423-36.
29. Nawrocki ST, Carew JS, Pino MS, et al. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 2005;65:11658-66.
30. Iwakoshi NN, Lee AH Glimcher LH. The X-box binding protein-1 transcription factor is required for plasma cell differentiation and the unfolded protein response. Immunol Rev 2003;194:29-38.
31. Iwakoshi NN, Lee AH, Vallabhajosyula P, et al. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat Immunol 2003;4:321-9.
32. Meister S, Schubert U, Neubert K, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 2007;67:1783-92.
33. Ikezoe T, Hisatake Y, Takeuchi T, et al. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res 2004;64:7426-31.
34. Schmidtke G, Emch S, Groettrup M, Holzhutter HG. Evidence for the existence of a non-catalytic modifier site of peptide hydrolysis by the 20S proteasome. J Biol Chem 2000;275:22056-63.
35. Coffinier C, Hudon SE, Farber EA, et al. HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells. Proc Natl Acad Sci U S A 2007;104:13432-7.
36. Gills JJ, Lopiccolo J, Tsurutani J, et al. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res 2007;13:5183-94.